Plasma Renin Activity: Which Tests to Order Alongside

What Plasma Renin Activity Actually Measures

PRA quantifies the enzymatic activity of renin by measuring the rate at which angiotensinogen is converted to angiotensin I in a patient's plasma sample over a set incubation period. The result is reported in nanograms of angiotensin I generated per milliliter per hour (ng/mL/hr). This differs from a direct renin concentration (DRC) assay, which measures the mass of renin protein itself using immunometric methods 1.

The distinction matters clinically. PRA reflects both the quantity of renin and the availability of its substrate (angiotensinogen), while DRC measures only renin mass. In patients on oral estrogen therapy, angiotensinogen levels rise, which can inflate PRA readings without a true change in renin secretion 2. The 2016 Endocrine Society guideline for primary aldosteronism accepts either PRA or DRC for ARR screening but notes that labs must establish their own assay-specific cutoffs 3.

A PRA result means very little in isolation. It gains diagnostic power only when paired with other analytes that reveal the physiological context behind the number.

Serum Aldosterone: The Essential Companion Test

Aldosterone is the single most important test to order with PRA. The aldosterone-to-renin ratio (ARR) is the recommended screening tool for primary aldosteronism according to both the Endocrine Society and the American Association of Clinical Endocrinologists 3.

The standard screening threshold is an ARR above 30 (ng/dL per ng/mL/hr) with a concurrent aldosterone level of 10 ng/dL or higher. In the PASO study (N=1,156), which remains the largest prospective cohort on primary aldosteronism outcomes, subtype-specific treatment guided by paired aldosterone and renin testing produced complete biochemical success in 94% of adrenalectomy patients at 12 months 4.

Ordering PRA without aldosterone is a common but avoidable error. A suppressed PRA of 0.1 ng/mL/hr could indicate primary aldosteronism, chronic volume overload from salt-sensitive essential hypertension, or even a lab artifact from delayed specimen processing. The aldosterone level resolves that ambiguity.

Both samples should be drawn from the same venipuncture event, ideally between 0800 and 1000 after the patient has been upright for at least two hours and seated for 5 to 15 minutes. The Endocrine Society guideline states: "The ARR is the most reliable means of screening for PA, and the test should be applied liberally" 3.

Basic Metabolic Panel: Potassium, Sodium, and Creatinine

Serum potassium must be measured alongside PRA and corrected to the normal range before the ARR can be reliably interpreted. Hypokalemia stimulates renin secretion independently of the renin-angiotensin-aldosterone system (RAAS) set point, which raises PRA and may mask the suppressed renin that characterizes primary aldosteronism 3.

In a cross-sectional analysis of 5,181 patients referred for suspected primary aldosteronism, 37% had hypokalemia at screening. Among those with confirmed bilateral adrenal hyperplasia, the false-negative ARR rate was 22% when potassium was below 3.0 mEq/L 5.

Serum sodium provides complementary data. A sodium level above 145 mEq/L alongside suppressed PRA and elevated aldosterone strengthens the suspicion for mineralocorticoid excess. Sodium below 135 mEq/L with high PRA points toward secondary causes of renin elevation such as renal artery stenosis, diuretic use, or heart failure.

Creatinine and estimated GFR round out the metabolic panel. Chronic kidney disease (CKD stage 3b and beyond) alters the RAAS axis significantly, and the Endocrine Society acknowledges that ARR interpretation is less reliable when eGFR falls below 30 mL/min/1.73 m² 3.

Morning Cortisol: Ruling Out Cushing Syndrome and Glucocorticoid Excess

When evaluating secondary hypertension, a morning serum cortisol (or a 1 mg overnight dexamethasone suppression test) should be ordered alongside the renin-aldosterone panel. The reason is practical. Primary aldosteronism and Cushing syndrome share overlapping presentations: hypertension, hypokalemia, and metabolic syndrome. Missing cortisol excess while chasing an aldosterone diagnosis delays correct treatment.

A 2019 retrospective study of 348 patients referred for adrenal incidentaloma found that 11.5% had subclinical hypercortisolism coexisting with an abnormal ARR 6. These patients had worse cardiovascular risk profiles than those with either condition alone. The AACE/ACE guideline on adrenal incidentalomas recommends screening for both cortisol and aldosterone excess whenever an adrenal nodule is detected 7.

A single morning cortisol below 5 mcg/dL generally excludes Cushing syndrome. Values above 15 mcg/dL are physiologically normal. The gray zone between 5 and 15 mcg/dL warrants the 1 mg dexamethasone suppression test, with a post-suppression cortisol above 1.8 mcg/dL considered a positive screen 8.

Thyroid Panel and Catecholamines: Completing the Secondary Hypertension Workup

For patients under age 40 with new-onset hypertension, or for any patient with resistant hypertension (blood pressure above goal on three agents including a diuretic), a comprehensive secondary hypertension panel is appropriate. Renin and aldosterone are one piece. The full panel typically adds TSH, free T4, and fractionated plasma metanephrines 9.

Pheochromocytoma occurs in roughly 0.2 to 0.6% of all hypertensive patients, but in 1 to 5% of those with resistant hypertension 10. Fractionated plasma metanephrines carry a sensitivity above 96% for pheochromocytoma and should be drawn supine after 20 minutes of rest to minimize false-positive normetanephrine elevations.

TSH screens for both hyper- and hypothyroidism as contributors to blood pressure dysregulation. Hyperthyroidism increases cardiac output and lowers systemic vascular resistance, producing systolic hypertension. Hypothyroidism raises diastolic blood pressure through increased peripheral resistance.

These tests do not need to be drawn at the same time as PRA, but ordering them during the same workup visit reduces patient burden and accelerates diagnosis. Dr. William F. Young Jr., writing in the Journal of Clinical Endocrinology and Metabolism, noted: "The clinician who does not screen for secondary causes in resistant hypertension will miss treatable, sometimes curable, conditions in up to 20% of that population" 11.

Medication Adjustments Before Testing

Several common antihypertensives alter PRA and aldosterone levels enough to invalidate screening. The medication hold protocol is as important as the test order itself.

Mineralocorticoid receptor antagonists (spironolactone, eplerenone) must be stopped at least four weeks before ARR screening. These drugs raise PRA and aldosterone simultaneously, distorting the ratio in both directions depending on the patient's underlying physiology 3.

Beta-blockers suppress renin secretion, which can produce a falsely elevated ARR even when aldosterone is normal. ACE inhibitors and angiotensin receptor blockers (ARBs) raise PRA through feedback disinhibition and may normalize an otherwise pathologic ARR. Diuretics (especially thiazides and loop diuretics) stimulate renin through volume depletion.

The Endocrine Society recommends transitioning patients to verapamil SR (sustained-release) and/or doxazosin for blood pressure control during the washout period. These two agents have minimal impact on the RAAS axis. Verapamil SR at 120 to 240 mg daily combined with doxazosin 2 to 8 mg at bedtime manages blood pressure adequately in most patients while preserving test validity 3.

For patients who cannot safely stop beta-blockers (heart failure with reduced ejection fraction, post-myocardial infarction), the clinician should note the medication on the lab order and interpret the ARR with the understanding that a suppressed PRA may be pharmacologic rather than pathologic.

Confirmatory Testing After a Positive ARR Screen

A positive ARR is a screening result. It is not diagnostic. Confirmatory testing is required before proceeding to adrenal CT or adrenal vein sampling.

Four confirmatory protocols are accepted by the Endocrine Society 3:

Oral sodium loading test. The patient consumes more than 200 mEq of sodium daily for three days. On day three, a 24-hour urine collection measures aldosterone, sodium, and creatinine. Urinary aldosterone above 12 mcg/24 hours (with urinary sodium above 200 mEq confirming adequate salt loading) is a positive result.

Intravenous saline infusion test. Two liters of 0.9% saline are infused over four hours. Post-infusion plasma aldosterone above 10 ng/dL confirms autonomous aldosterone secretion. This test is contraindicated in patients with uncontrolled heart failure.

Fludrocortisone suppression test. The patient takes 0.1 mg fludrocortisone every six hours for four days while receiving sodium and potassium supplementation. On day four, an upright plasma aldosterone above 6 ng/dL at 1000, with PRA below 1 ng/mL/hr, is diagnostic. This test is the most sensitive but requires inpatient monitoring.

Captopril challenge. The patient receives 25 to 50 mg of captopril orally. Aldosterone is measured at baseline and at one and two hours. Failure of aldosterone to suppress below 30% of baseline, or an absolute level remaining above 8.5 ng/dL, suggests primary aldosteronism. This is the simplest outpatient option.

In the SPARTACUS trial (N=184), CT-based management was noninferior to adrenal vein sampling (AVS) for blood pressure and biochemical outcomes at one year, though AVS remains the gold standard for lateralization in patients who are surgical candidates 12.

How to Interpret High, Low, and Normal PRA

Normal range. PRA in a seated, salt-replete adult typically falls between 0.25 and 5.82 ng/mL/hr, though reference ranges vary by assay and laboratory. Always interpret PRA against the specific lab's reference interval.

High PRA (above the upper reference limit) points toward secondary hyperaldosteronism or a non-aldosterone cause of renin elevation. Common causes include renal artery stenosis, renin-secreting tumors (rare), dehydration, chronic diuretic use, and heart failure. High PRA with high aldosterone suggests secondary hyperaldosteronism. High PRA with normal or low aldosterone may indicate ACE inhibitor or ARB use, or an adrenal insufficiency state.

Low PRA (below 0.5 ng/mL/hr in most assays) combined with high aldosterone is the hallmark of primary aldosteronism. Low PRA with low aldosterone occurs in states of mineralocorticoid excess from non-aldosterone sources: licorice ingestion, Liddle syndrome, congenital adrenal hyperplasia (11-beta-hydroxylase deficiency), or exogenous fludrocortisone.

Dr. John W. Funder, lead author of the Endocrine Society's primary aldosteronism guideline, has emphasized: "A suppressed renin in the context of hypertension should never be dismissed as a normal variant. It is a signal that demands paired aldosterone measurement" 3.

Strategies for Raising or Lowering PRA

PRA is a physiologic marker, not a treatment target. Clinicians do not aim to change PRA directly but rather treat the condition that produced the abnormal value.

To address high PRA caused by volume depletion: correct dehydration, reduce diuretic doses, and assess dietary sodium intake. In renovascular hypertension with high PRA, renal artery revascularization (angioplasty with stenting for atherosclerotic disease) or medical management with ACE inhibitors may be appropriate 13.

To address low PRA from primary aldosteronism: unilateral adrenalectomy for lateralized disease produces biochemical cure rates of 94 to 99% and hypertension cure in 37 to 42% of patients at long-term follow-up 4. For bilateral disease or patients who decline surgery, mineralocorticoid receptor antagonists (spironolactone 25 to 100 mg daily, or eplerenone 50 to 200 mg daily) are first-line medical therapy. Spironolactone is more potent but carries antiandrogenic side effects at higher doses.

Dietary sodium restriction to below 2,300 mg daily supports blood pressure control in both high-renin and low-renin hypertension. The DASH-Sodium trial (N=412) demonstrated a 7.1 mmHg mean reduction in systolic blood pressure with sodium restriction from 3,300 mg to 1,500 mg daily in hypertensive participants 14.

Pre-Analytic Variables That Wreck Results

PRA is one of the most pre-analytically sensitive tests in clinical medicine. Getting the paired panel right means controlling for posture, timing, specimen handling, and dietary sodium.

Posture. PRA increases 2- to 4-fold from supine to upright. The Endocrine Society recommends that the patient be seated for 5 to 15 minutes before the draw 3. Lying down for the draw will lower PRA and may produce a falsely elevated ARR.

Time of day. Both renin and aldosterone follow a circadian rhythm, peaking in the early morning. Draws should occur between 0800 and 1000 for consistency with published reference ranges.

Specimen handling. PRA samples must be collected in chilled EDTA tubes and centrifuged promptly in a refrigerated centrifuge. Specimens left at room temperature generate angiotensin I ex vivo, falsely elevating PRA. Some labs now prefer direct renin concentration assays specifically because DRC is less vulnerable to handling errors 1.

Dietary sodium. Extreme sodium restriction (below 50 mEq/day) stimulates renin strongly enough to normalize the ARR in true primary aldosteronism. A concurrent 24-hour urine sodium confirms whether the patient was on a liberal salt diet (above 100 mEq) at the time of testing.

Getting the draw conditions wrong is more common than getting the test selection wrong. A perfectly ordered panel collected under improper conditions produces uninterpretable data.